Company
South KoreaHanAll BioPharma Co., Ltd. is a leading Korean pharmaceutical company focused on drug delivery, biotherapeutics, and new small molecule discovery.
Private/Public:
public
Phone:02-550-8800
Fax:02-550-8400
Email:[email protected]
Website:http://en.hanall.co.kr/main
Address:Daewoong Building FL9, 12 Bongeunsaro 114-gil, Gangnam-gu, Seoul, South Korea
1973
Since
1
Country
0
Top Service Category
0
Sub-Service Category
Top Services
South Korea
- (12.Jan.2021) Immunovant Provides Corporate Update
- (16.Nov.2020) Harbour BioMed Will Present Results From Its Phase II Clinical Trial With Tanfanercept (HBM9036) in Patients With Moderate-To-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society
- (30.Sep.2020) Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia
- (25.Aug.2020) Immunovant Announces Positive Topline Results From Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401, a Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Myasthenia Gravis
- (02.Jun.2020) Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves' Ophthalmopathy
- (27.May.2020) JW Pharm to Suffer Most From Suspended Sale of 31 Diabetes Drugs
- (11.May.2020) HanAll's Profit Increases Despite Sales Drop in Q1
- (21.Apr.2020) Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder
- (15.Apr.2020) Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Immune Thrombocytopenia
- (30.Mar.2020) Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-Of-Concept Study of IMVT-1401, a Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
- (21.Feb.2020) Harbour BioMed Announces Completion of Phase 1 Study in China of HBM9161, an Anti-FcRn Antibody
- (28.Jan.2020) HanAll Biopharma/Daewoong Announces Topline Results for HL036 Phase 3 (VELOS-2) Study at a Press Conference
- (21.Jan.2020) HanAll Remains Positive of Eye Treatment's Efficacy Despite Initial Failure